CA-ONCLUSIVE
Today, leading technology investor Symphony Technology Group “STG” completes its acquisition of Kantar ’s Reputation Intelligence business, and with it announces the additional purchases of PRgloo and Onclusive . Together the three businesses merge to create a new global media monitoring, measurement, and workflow management partner for PR and communications.
The new standalone company will operate under the name ‘Onclusive’ reflecting the inclusive and scalable nature of its newly combined offer and its commitment to accelerating investment in tech-powered platforms and solutions.
The company builds on the consultative strengths and scale of Europe’s largest media monitoring and analysis provider, Kantar Reputation Intelligence; UK-based PRgloo’s industry-leading media relations and workflow management platform and US-based Onclusive’s AI technology and data science.
Commenting on the new company, Chief Commercial Officer of the newly-formed Onclusive, Petra Masinova explained: “We’ve always admired each other’s strengths and we’ve increasingly teamed up on programmes to help solve clients’ needs. Today we accelerate our natural evolution to become one company, amplifying our strengths and supporting our clients with leading insights, technology and expertise together under one roof.”
Dan Beltramo, Chief Innovation Officer of the new Onclusive , also praised the union: “Onclusive is a technology and innovation pioneer in media monitoring and analytics while Kantar Reputation Intelligence is a leader in customer service with top-tier European coverage and market-leading insights capabilities. It brings us scale and ambition for global leadership.”
Samantha Deeks, VP Customer Experience at new Onclusive added: “Building on PRgloo’s customer-centric design approach, we’re delighted to work with like-minded industry leaders to build a scalable and agile business; one which actively listens and responds to the needs of its clients as they navigate an increasingly complex communications environment.”
Managing Director at STG, J.T. Treadwell , said: “Last year STG made clear its intention to create a market leading insights and software company through the proposed acquisition of Kantar Reputation Intelligence. Completing that acquisition is a major first step and the additional capabilities brought by Onclusive and PRgloo widen the scope of our commitment to providing best-in-class solutions for PR and Communications teams, both now and in the future.”
Onclusive will serve more than 9,000 clients, including many of the world’s biggest brands, across 130 markets. The company has over 1,100 employees based in the USA, UK, Ireland, France, Italy, Spain, Germany and Australia.
Onclusive North America Managing Director, Sean O’Neal , continued: “Our clients were our matchmakers – they told us they wanted one trusted partner to help them access and integrate our combined best-in-class services. We listened and from today Onclusive will help every client – from small enterprises to multi-national public and private organisations – shape, manage and evaluate their communications strategies.”
From today, clients can access the new Onclusive’s full range of services, supporting them at every stage of the communications cycle. Existing services continue uninterrupted.
About Onclusive
Onclusive is a global partner for PR and Communications success. We bring together Kantar Reputation Intelligence, the largest media monitoring and measurement service in Europe, with the best-in-class tools of PRgloo, and Onclusive’s own powerful AI and data science. Our technology, insights and expertise make sense of the fractured, fast-moving media world, helping you manage, monitor and measure your communications activity. Elevate your performance and prove and improve your value with Onclusive on your side.
About STG Partners
STG is a private equity partner to market leading companies in software, data analytics and software-enabled technology services sectors. The firm brings expertise, flexibility, and resources to build strategic value and unlock the potential of innovative companies. Partnering to build customer-centric, market leading portfolio companies, STG seeks to create sustainable foundations for growth that bring value to its companies. The firm is dedicated to transforming and building outstanding technology companies in partnership with leading management teams. STG and its predecessor, Symphony Technology Group (“Symphony”), have managed approximately $6 billion in total capital. For more information, please visit stgpartners.com
Kantar Reputation Intelligence – The leader in earned media tracking and measurement in Europe. Reputation Intelligence provides trusted insights on corporate, PR and brand coverage in 130+ markets to brands can understand and manage how audiences and influencers see them, globally and locally.
Onclusive – Empowers the world’s leading brands and agencies to modernize communications, increase performance and demonstrate value. The inventors of PR Attribution™ and Power of Voice™, Onclusive measures the true impact of earned, owned and social content on a company’s bottom line.
PRgloo – The complete media relations platform. PRgloo combines easy to use tools with exceptional analysis to make PR professionals’ lives easier by giving them the tools they need to do their jobs well.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220104005044/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Natus Sensory Appoints Arne Boye Nielsen to Board of Directors8.1.2026 08:00:00 CET | Press release
Natus Sensory, a global leader in sensory and diagnostic solutions, today announced the appointment of Arne Boye Nielsen to its Board of Directors, effective January 1, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260107392331/en/ Arne Boye Nielsen Arne brings more than 30 years of executive leadership experience in diagnostics and medical technology, most notably as President of Demant Diagnostics, where he built and scaled the business into a global leader over three decades. During his tenure, Arne played a central role in shaping Demant Diagnostics’ long-term strategy, portfolio expansion, and international growth, establishing it as a cornerstone of Demant’s global healthcare footprint. In addition to his executive leadership background, Arne brings extensive board experience. His deep expertise across diagnostics, governance, and value creation will further strengthen Natus Sensory’s Board as the company contin
4Moving Biotech Receives FDA IND Clearance for 4P004, Strengthening Its Position as a Leading Innovator in Disease-Modifying Osteoarthritis Therapeutics8.1.2026 07:30:00 CET | Press release
FDA IND clearance enabling the worldwide expansion of the INFLAM MOTION Phase 2a trial, involving major U.S. sites Advancing the first clinical proof of concept in OA with a first-in-class intra-articular GLP-1 agonist A holistic clinical strategy design establishing the foundation for a future accelerated approval pathway 4Moving Biotech (4MB), a clinical stage biotechnology company developing next-generation, disease-modifying therapies for osteoarthritis (OA), today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for 4P004, enabling the expansion of the Phase 2a INFLAM MOTION clinical trial into the United States (US). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260107798042/en/ 4Moving Biotech (4MB), a clinical stage biotechnology company developing next-generation, disease-modifying therapies for osteoarthritis (OA), today announced that the U.S. F
Organon Enters into a Commercialization Agreement for Daiichi Sankyo’s Nilemdo®in France, Denmark, Iceland, Sweden, Finland and Norway8.1.2026 07:30:00 CET | Press release
The agreement builds on Organon’s cardiovascular disease portfolio, leveraging expertise to expand access to new treatments for patients with dyslipidemia, especially statin-intolerant patients.This collaboration addresses a critical gap in care that disproportionately affects women, who are at a 47% higher risk of developing statin intolerance compared to men.i Organon today announced that it has entered into an agreement with Daiichi Sankyo Europe to commercialize Nilemdo® (bempedoic acid) in France, Denmark, Iceland, Sweden, Finland and Norway. Nilemdo® is a new, first-in-class drug indicated for patients with high cholesterol and cardiovascular disease risk. It provides an alternative treatment for patients that cannot be treated effectively with statins.ii “This collaboration combines Organon’s commercial agility with Daiichi Sankyo’s expertise in cardiovascular innovation to bring Nilemdo® to patients in France, Denmark, Iceland, Sweden, Finland and Norway,” says Thibault Crosnie
Prodapt Earns ISO 42001 Certification, the New Global Benchmark for Responsible Enterprise AI8.1.2026 07:00:00 CET | Press release
Prodapt today announced that it has been awarded the ISO 42001 certification, the world’s first and the only global standard for AI Management Systems (AIMS). Marking a significant milestone in its journey, Prodapt is setting a higher benchmark to deliver secure, ethical, and scalable AI for global enterprises. ISO 42001 lays a rigorous framework for governing AI across strategy, technology, and operations. The certification, awarded by an independent accredited body, validates Prodapt’s enterprise-grade AI management framework, including executive-led oversight, strong technology foundations, and disciplined operational processes. These measures ensure AI systems are responsibly designed, deployed, monitored, and evolved throughout their lifecycle. The evaluation emphasizes risk management, ethical AI practices, transparency, and scalability, confirming Prodapt’s ability to proactively identify and mitigate risks while ensuring accountability in AI-driven outcomes. Human-in-the-loop c
Azafaros to Present at J.P. Morgan’s 44th Annual Healthcare Conference8.1.2026 07:00:00 CET | Press release
Azafaros, a company building a portfolio to become a leader in lysosomal storage disorders with the goal of addressing neurological symptoms, today announced that it will present at J.P. Morgan’s 44th Annual Healthcare Conference on Thursday, January 15. The company’s presentation will begin at 9:30 am PT/12:30 am ET/6:30 am CET. The presentation will focus on the company’s lead product, nizubaglustat, a potential treatment for rare lysosomal storage disorders with neurological involvement including GM1/GM2 gangliosidoses and Niemann-Pick type C disease ((NPC). Two pivotal Phase 3 studies investigating nizubaglustat in GM1/GM2 gangliosidoses and NPC are currently enrolling, with data expected in 2027. The studies build on positive data from a robust clinical program including the Phase 2 RAINBOW study and the PRONTO natural history study. The Phase 3 studies are financed following the company’s successful completion of €132 million series B round completed in 1H 2025. About nizubaglust
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom